Received Feb 10, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | UNK | — | — |
Grown a third testicle, which has greatly improved his sex life; Grown a third testicle, which has greatly improved his sex life; Grown a third testicle, which has greatly improved his sex life; This is a solicited report received from a consumer, Program ID: . A male patient received BNT162b2 (BNT162B2), as dose number unknown, single (Batch/Lot number: unknown) for COVID-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: THERAPEUTIC RESPONSE UNEXPECTED (medically significant), ABNORMAL ORGAN GROWTH (medically significant), LIBIDO INCREASED (medically significant), outcome "unknown" and all described as "Grown a third testicle, which has greatly improved his sex life". The patient had received the Pfizer COVID vaccine in 2019 (as reported) and has since grown a third testicle, which has greatly improved his sex life; abnormal growth after vaccine administration. The reporter's assessment of the causal relationship of "grown a third testicle, which has greatly improved his sex life" with the suspect product(s) BNT162b2 was not provided at the time of this report. Since no determination has been received, the case is managed based on the company causality assessment. No follow-up attempts are possible. Batch/lot number is not provided, and it cannot be obtained.; Sender's Comments: As there is limited information in the case provided, the causal association between the events therapeutic response unexpected, abnormal organ growth, and libido increased and the suspect drug BNT162B2 cannot be excluded. The case will be reassessed once new information is available. The impact of this report on the benefit-risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, ethics committees and investigators, as appropriate.